Researchers sought to determine whether glofitamab would induce responses in real-world cases of relapsed or refractory DLBCL.

The combination of glofitamab (Columvi) plus polatzumab vedotin (Polivy) demonstrated high efficacy and durable responses in patients with relapsed/refractory large B-cell lymphoma (LBCL), according ...

A phase 1 trial reveals that combining radiotherapy with immunotherapy enhances response rates in B-cell lymphomas while maintaining manageable safety profiles.

ANTLER phase 1 data demonstrate efficacy and durability on par with autologous CAR-T cell therapy and safety allows for outpatient use, highlighting its potential as a best-in-class allogeneic CAR-T ...

A cancer diagnosis for a beloved family dog is heart-wrenching. Not all lymphomas are the same, however, and prognoses differ for each.

Researchers assessed whether combination mosunetuzumab and polatuzumab vedotin would reduce the risk of disease progression or death in patients with LBCL.

A 79-year-old man was admitted to a hospital in Guangzhou, China, with progressive dyspnea and edema. Echocardiography and ...

At 31, Rohan should have been planning his next trek in Himachal, not learning how to pronounce adenocarcinoma. Fit, cheerful ...

At 31, Rohan should have been planning his next trek in Himachal, not learning how to pronounce adenocarcinoma. Fit, cheerful, and the office’s go-to for wellne ...

As PET scans fall short, blood-based circulating tumor DNA testing shows promise in monitoring large B-cell lymphoma ...

Researchers at the University of Southampton have identified a new subtype of lymphoma that could pave the way to improved and more targeted treatments for some blood cancer patients. The cancer ...

Many things are evaluated when doctors are putting a treatment plan together for prostate cancer patients. A new study says ...